Skip to main content
SpringerLink
Log in

Hyponatremia in Cirrhosis: Evaluation and Treatment

  • Chapter
  • First Online:
Hyponatremia

Abstract

Hyponatremia is a common complication in patients with cirrhosis that is related to impairment in the renal capacity to eliminate solute-free water. The main pathogenic factor associated with hyponatremia is a non-osmotic hypersecretion of vasopressin which acts in the V2-receptors in the renal collecting ducts. A decrease in serum sodium concentration is associated with an increased risk of hepatic encephalopathy. Hyponatremia is associated with poor prognosis in patients with cirrhosis. There is evidence that hyponatremia also represents a risk factor for liver transplantation, as it is associated with an increased frequency of complications and a decreased short-term survival after transplantation. Classical treatment of hyponatremia is based on fluid restriction, but is poorly effective. The current pharmacological approach to hyponatremia has advanced with vaptans, a new family of drugs which antagonize V2-receptors in the renal collecting ducts. Short-term treatment with vaptans is associated with an increase in serum sodium concentration and improvement in health-related quality of life. Nevertheless, information on the use of vaptans in cirrhosis is limited and further long-term studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ginès P, Cárdenas A, Schrier R. Liver disease and the kidney. In: Schrier R, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2179–205.

    Google Scholar 

  2. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–9.

    Article  PubMed  CAS  Google Scholar 

  3. Ginès P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851–64.

    Article  PubMed  Google Scholar 

  4. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance and management. Hepatology. 2008;48:1002–10.

    Article  PubMed  Google Scholar 

  5. Ginès P, Angeli P, Lenz K, Möller S, Moore K, Moreau R, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.

    Article  Google Scholar 

  6. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–94.

    Article  PubMed  Google Scholar 

  7. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535–42.

    Article  PubMed  CAS  Google Scholar 

  8. Biggins S, Rodriguez HJ, Bachetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41:32–9.

    Article  PubMed  CAS  Google Scholar 

  9. Londoño MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283–90.

    Article  PubMed  Google Scholar 

  10. Londoño MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130:1135–43.

    Article  PubMed  Google Scholar 

  11. Dawwas MF, Lewsey JD, Neuberger J, et al. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007;13:1115–24.

    Article  PubMed  Google Scholar 

  12. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.

    Article  PubMed  CAS  Google Scholar 

  13. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–60.

    Article  PubMed  Google Scholar 

  14. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336–43.

    Article  PubMed  Google Scholar 

  15. Pereira G, Guevara M, Fagundes C, Solá E, Rodríguez E, Fernández J, et al. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol. 2012;56:1040–6.

    Article  PubMed  Google Scholar 

  16. Ishikawa S, Schrier RW. Pathogenesis of hyponatremia: the role of arginine vasopressin. In: Ginès P, Arroyo V, Rodes J, Schrier R, editors. Ascites and renal dysfunction in liver disease. 2nd ed. Oxford: Blackwell; 2005. p. 305–14.

    Google Scholar 

  17. Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998;449:251–76.

    Article  PubMed  CAS  Google Scholar 

  18. Kwon TH, Hager H, Nejsum LN, et al. Physiology and pathophysiology of renal aquaporins. Semin Nephrol. 2001;21:231–8.

    Article  PubMed  CAS  Google Scholar 

  19. Nielsen S, Frokiaer J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82:205–44.

    PubMed  CAS  Google Scholar 

  20. Elhassan EA, Schrier RW. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens. 2011;20:161–8.

    Article  PubMed  CAS  Google Scholar 

  21. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104:1382–9.

    Article  PubMed  Google Scholar 

  22. Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46.

    Article  PubMed  Google Scholar 

  23. Guevara M, Baccarro ME, Rios J, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 2010;30:1137–42.

    Article  PubMed  CAS  Google Scholar 

  24. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57:1156–65.

    Article  PubMed  CAS  Google Scholar 

  25. Córdoba J, García-Martinez R, Simón-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis. 2010;25:73–80.

    Article  PubMed  Google Scholar 

  26. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: course, predictive factors and prognosis. Hepatology. 1994;20:1495–501.

    Article  PubMed  CAS  Google Scholar 

  27. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993;105:229–36.

    PubMed  Google Scholar 

  28. Solà E, Guevara M, Rodriguez E, Barreto R, Pavesi M, Arroyo V, et al. Hyponatremia is a major factor of the impaired health-related quality of life in patients with cirrhosis and ascites. J Hepatol. 2012;57:1199–206.

    Article  Google Scholar 

  29. Jalan R, Mookerjee R, Cheshire L, Williams R, et al. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol. 2007;46:232A.

    Article  Google Scholar 

  30. McCormick PA, Mistry P, Kaye G, Burroughs AK, McIntyre N. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut. 1990;31:204–7.

    Article  PubMed  CAS  Google Scholar 

  31. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–32.

    Article  PubMed  CAS  Google Scholar 

  32. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–91.

    Article  PubMed  CAS  Google Scholar 

  33. Gerbes AL, Gulberg V, Ginès P, et al. VPA study group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–9.

    Article  PubMed  CAS  Google Scholar 

  34. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.

    Article  PubMed  CAS  Google Scholar 

  35. Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204–13.

    Article  PubMed  Google Scholar 

  36. Cárdenas A, Ginès P, Marotta P, et al. The safety and efficacy of tolvaptan, an oral vasopressin antagonist in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571–8.

    Article  PubMed  Google Scholar 

  37. O'Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl. 2009;15:1325–9.

    Article  PubMed  Google Scholar 

  38. Wong F, Ginès P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53:283–90.

    Article  PubMed  CAS  Google Scholar 

  39. Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis. Efficacy and safety across the spectrum of ascites severity. Gut. 2012;61:108–16.

    Article  PubMed  CAS  Google Scholar 

  40. Okita K, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45:979–87.

    Article  PubMed  CAS  Google Scholar 

  41. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Unit, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Barcelona, Spain

    Elsa Solà & Pere Ginès

  2. GI Unit, Hospital Clinic de Barcelona, Barcelona, Spain

    Andrés Cárdenas

  3. Endoscopy Unit, Institute of Digestive Diseases, Hospital Clinic de Barcelona, Barcelona, Spain

    Andrés Cárdenas

  4. University of Barcelona School of Medicine, Barcelona, Spain

    Elsa Solà, Andrés Cárdenas & Pere Ginès

Authors
  1. Elsa Solà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrés Cárdenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pere Ginès
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pere Ginès .

Editor information

Editors and Affiliations

  1. Section of Nephrology and Hypertension, Tulane University Health Sciences Center, Tulane Ave 1430, New Orleans, 70112, Louisiana, USA

    Eric E. Simon

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Solà, E., Cárdenas, A., Ginès, P. (2013). Hyponatremia in Cirrhosis: Evaluation and Treatment. In: Simon, E. (eds) Hyponatremia. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6645-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6645-1_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6644-4

  • Online ISBN: 978-1-4614-6645-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation